Bristol-Myers to pay $1.85 billion in cancer deal with Nektar

(Reuters) – Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion for a global development and profit-sharing deal on a promising Nektar cancer drug, the companies announced on Wednesday.

Source: Reuters Medical News